Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable HBV DNA

This study has been completed.
Sponsor:
Collaborator:
Pusan National University Hospital
Information provided by (Responsible Party):
Sang Hoon Ahn, Yonsei University
ClinicalTrials.gov Identifier:
NCT00625339
First received: February 19, 2008
Last updated: May 7, 2012
Last verified: May 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2010
  Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)